Collegium Pharmaceutical (COLL) Repositioning: Shifting Focus from Pain Management to ADHD
Yahoo Finance
Collegium Pharmaceutical is shifting its focus from pain management to ADHD, signaling a strategic repositioning in its business approach. The company's stock has experienced a decline, reflecting market reactions to this change in emphasis. The Third Avenue Small-Cap Value Fund's Q3 2026 performance highlights mixed contributions from various stocks, with Collegium Pharmaceuticals being a detractor.
All articles from 2 November 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.
Get this news by email
Daily or as a weekly roundup in your inbox. You confirm your address first; every email has an unsubscribe link. For another topic or language, use the subscribe page.